Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (Nasdaq: INM)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended December 31, 2024
Business Overview: InMed is a clinical-stage pharmaceutical company developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs (Alzheimer's, dry AMD, Epidermolysis Bullosa). It operates two segments: InMed Pharma (R&D) and BayMedica Commercial (manufacturing and sale of bulk rare cannabinoids for the health and wellness sector).
Key Corporate Event: On November 14, 2024, the Company effected a 20-for-1 reverse stock split to regain compliance with Nasdaq listing requirements.
Key Financial Metrics
| Metric (USD) | 3 Months Ended Dec 31, 2024 | 6 Months Ended Dec 31, 2024 | 6 Months Ended Dec 31, 2023 |
|---|---|---|---|
| Total Revenue | $1,111,707 | $2,376,345 | $2,142,062 |
| Gross Profit | $460,894 | $954,307 | $345,384 |
| Net Loss | $(2,575,024) | $(4,252,892) | $(4,015,013) |
| Net Loss Per Share (Basic/Diluted) | $(3.64) | $(6.43) | $(14.21) |
| Cash and Cash Equivalents | $3,419,422 | $3,419,422 | $9,534,922 |
| Total Assets | $8,502,292 | $8,502,292 | $11,822,782 |
| Accumulated Deficit | $(113,328,651) | $(113,328,651) | $(105,415,222) |
Segment Performance (6 Months Ended Dec 31, 2024):
- InMed Pharma: Net loss of $(4,788,623). No revenue; expenses driven by R&D and G&A.
- BayMedica Commercial: Net income of $535,731. Revenue of $2,376,345 with a gross profit of $954,307.
Material Changes vs. Prior Period
- Revenue: Total revenue increased 11% year-over-year for the six-month period, driven by the BayMedica segment. However, BayMedica sales decreased 10% in the most recent quarter due to pricing pressure from competition.
- Profitability: Gross profit for the six-month period improved significantly (177% increase) primarily due to a reduction in inventory write-downs compared to the prior year.
- Operating Expenses: Total operating expenses increased 6% year-over-year for the six-month period. R&D expenses in the InMed Pharma segment rose 86% in the quarter due to increased external contractor costs for INM-901 and INM-089 programs.
- Finance Expenses: A new finance expense of $351,549 was recorded in the current period related to fees incurred under a new Standby Equity Purchase Agreement (SEPA).
- Liquidity: Cash and cash equivalents decreased by approximately $3.15 million during the six-month period, compared to an increase of $0.62 million in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
Going Concern: Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance date. The Company expects its current cash ($3.5M) plus proceeds from January 2025 financing ($2.9M) to fund operations only through the end of Q2 2025.
Financing Activities:
- SEPA: Entered into a $10 million Standby Equity Purchase Agreement on December 13, 2024. Issued shares for $2.46 million in January 2025 (subsequent event).
- ATM: Issued shares for $1.4 million gross proceeds during the six-month period. The S-3 registration statement expired on February 10, 2025.
Outlook and Milestones:
- INM-901 (Alzheimer's): Announced positive preclinical results in January 2025 showing reduced neuroinflammation markers.
- INM-089 (Dry AMD): Selected an intravitreal formulation for further preclinical studies in February 2025.
- INM-755 (Epidermolysis Bullosa): Completed Phase 2 trial showing positive anti-itch activity; seeking strategic partners.
Risks and Contingencies:
- Legal: Ongoing dispute with a Licensor regarding a Patent License Agreement; potential for arbitration but no lawsuit filed as of filing date.
- Corporate Governance: Director Janet Grove resigned following shareholder vote at the 2024 AGM; Board is searching for a replacement.
- Market Risk: Potential impact of U.S. tariffs on Canadian imports announced in February 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.9M raised in January 2025 to bridge the gap to Q2 2025 and the timeline for the next capital raise.
- SEPA Terms: Review the specific pricing mechanisms and "Exchange Cap" limitations of the new $10M SEPA to understand dilution risks.
- BayMedica Margins: Monitor the trend of inventory write-downs and pricing pressure in the rare cannabinoid market, which heavily influences the Company's only revenue stream.
- Legal Dispute: Track the status of the Patent License Agreement dispute with the third-party Licensor for potential arbitration outcomes.
- Regulatory Compliance: Confirm continued compliance with Nasdaq listing requirements following the reverse stock split.